Alkem MedTech Acquires Occlutech to Boost Cardiovascular Devices

Publisher: The Insight Partners

Alkem MedTech Pvt Ltd, the medical devices arm of India’s Alkem Laboratories Ltd, announced a binding offer to acquire a majority stake in Switzerland-based Occlutech Holding AG. Consequently, the acquisition marks Alkem MedTech’s strategic entry into the advanced cardiovascular devices market. The company plans to purchase up to 55% of Occlutech for approximately €99.4 million (about ?1,074 crore), thereby expanding its high-growth medical technologies portfolio.

The offer remains subject to statutory and regulatory approvals. Meanwhile, Alkem MedTech aims to complete the acquisition by June 2026, contingent on satisfying legal and investment clearance procedures. Therefore, this deal positions the company to expand globally and provide advanced structural heart solutions to patients worldwide.

Occlutech, headquartered in Switzerland, develops, manufactures, and sells minimally invasive cardiac implant systems. These devices treat congenital heart defects, prevent strokes, and manage heart failure. Moreover, the company operates facilities in Germany and Turkey while maintaining a global distribution network from Sweden, alongside clinical operations in the United States. Occlutech ranks among the top three global players in the cardiac implant segment, which underscores its prominence in the cardiovascular devices market.

In 2025, Occlutech reported unaudited revenue of €49.4 million, reflecting a three-year compound annual growth rate of 15.7%. Approximately 85% of its revenue comes from key markets in Europe and the United States. This demonstrates strong global demand for its solutions. Additionally, the company’s consistent performance highlights its robust market position.

Executive Chairman of Alkem Laboratories, B. N. Singh, stated that this acquisition opens long-term opportunities and strengthens Alkem’s vision to lead the medical devices sector. He highlighted that the move leverages the company’s pharmaceutical expertise to transform patient care through advanced cardiovascular devices.

Alkem MedTech CEO Kaustav Banerjee noted that Occlutech’s structural heart technology and world-class R&D provide a solid growth foundation. He added that the acquisition enables entry into high-value markets, including the United States, Japan, Germany, and Western Europe, where demand for advanced cardiac care continues to rise.

Occlutech CEO Tor Peters emphasized that collaborating with Alkem MedTech will accelerate innovation and expand access to advanced cardiac care worldwide. Both organizations plan to create value through ongoing research, development programs, and strategic cost optimization. Consequently, patients and healthcare providers could benefit from improved device availability and quality.

The rise in cardiovascular conditions in developing countries is closely tied to lifestyle changes and modernized facilities. Urbanization has reduced physical activity, while personal and social stress levels continue to grow, further increasing disease prevalence. Simultaneously, technological advancements in cardiovascular devices are improving healthcare infrastructure and services in these regions, thereby offering better treatment options.

Industry analysts observe that the global medical devices market is poised for strong growth. Structural heart interventions and cardiovascular devices remain key segments, driven by demographic changes, rising disease prevalence, and continuous technological innovation. Therefore, Alkem MedTech now stands at the forefront of this trend, ready to meet growing demand for minimally invasive cardiac solutions.

The acquisition also signals Alkem’s strategic shift from primarily pharmaceuticals to a diversified healthcare company with a broader technology portfolio. While the medical devices subsidiary previously focused on orthopedic implants, this deal significantly enhances its capabilities in cardiology. Moreover, it provides access to new markets and collaboration opportunities.

Experts believe that integrating Occlutech’s operations could improve Alkem MedTech’s competitive advantage in the cardiovascular devices sector. Successful integration will require aligning regulatory frameworks, supply chains, and distribution networks across multiple regions. However, the long-term benefits appear highly promising.

As regulatory approvals progress and transaction conditions are fulfilled, stakeholders worldwide will monitor how this acquisition shapes Alkem MedTech’s growth and impacts the global cardiovascular devices industry.